Browsing Category
Pharma Industry News
4729 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Ribo Life Science raises HKD1.8bn in Hong Kong IPO amid strong institutional support for siRNA growth strategy
Ribo Life Science’s HKEX IPO raised HKD 1.83B for siRNA drug development. See how it could reshape RNA biotech investment trends in Asia. Read more.
Mesoblast (ASX: MSB) ramps up GVHD play with record Ryoncil revenue and fresh $125m credit line
Ryoncil sales surged 60 percent for Mesoblast in Q4. Read how its $125M refinancing plan could reshape capital efficiency and future cell therapy expansion.
EMBRACE results prompt Sobi to engage regulators on emapalumab sepsis pathway
Sobi will advance emapalumab in IFNγ-driven sepsis after EMBRACE trial shows proof-of-concept. Find out what this pivot means for its strategy and the field.
Automated Industrial Robotics Inc. acquires KAON Automation to scale medical and life sciences manufacturing automation
Find out how Automated Industrial Robotics Inc.’s acquisition of KAON Automation strengthens its medical and life sciences automation platform.
MoonLake Immunotherapeutics says FDA supports existing clinical data for sonelokimab, announces investor day amid strong market reaction
Find out how MoonLake Immunotherapeutics gained FDA support for its sonelokimab data and why investors are watching its 2026 regulatory path closely.
Acrivon Therapeutics strengthens precision oncology pipeline with ACR-368 Phase 2b success and new AP3-enabled candidates
Find out how Acrivon Therapeutics is advancing precision oncology with positive ACR-368 Phase 2b data, EU trial expansion, and new AP3-enabled pipeline candidates.
Lilly to acquire Ventyx Biosciences (Nasdaq: VTYX) in a high-conviction bet on oral inflammation therapies
Eli Lilly is acquiring Ventyx Biosciences for $1.2B to advance oral inflammation therapies. Find out what this means for biotech M&A and chronic care strategy.
Amgen (NASDAQ: AMGN) bets on protein degradation with Dark Blue Therapeutics acquisition
Amgen acquires Dark Blue Therapeutics for up to $840M, expanding into MLLT1/3-targeted AML therapies. Find out what this means for oncology innovation today.
GSK wins approval in China for Nucala in eosinophilic COPD, expanding respiratory biologics reach
Find out how GSK’s Nucala just became the first biologic approved for eosinophilic COPD in China—and what it means for the future of respiratory care.
FDA clears GenEditBio to begin human testing of GEB-101, a first-in-class genome-editing therapy for TGFBI corneal dystrophy
Find out how GenEditBio's GEB-101 genome-editing therapy just cleared FDA to begin trials for TGFBI corneal dystrophy. Could it redefine in vivo editing?